Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.
More than 90% of patients with PsA who received guselkumab every 8 weeks in the DISCOVER-2 trial maintained minimal ...
New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.
In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...
Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...
GlobalData on MSN9h
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s diseaseAfter both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...
Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the ...
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...
According to GlobalData’s Sales and Forecast database, total sales for Tremfya are expected to reach $7.8 billion globally by 2029.
Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback